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IJCMalignant ascites is a common manifestation of advanced cancers, and treatment options are limited. The trifunctional
antibody catumaxomab (anti-epithelial cell-adhesion molecule x anti-CD3) represents a targeted immunotherapy for the
intraperitoneal (i.p.) treatment of malignant ascites secondary to epithelial cancers. In this phase II/III trial (EudraCT
2004-000723-15; NCT00836654), cancer patients (n 5 258) with recurrent symptomatic malignant ascites resistant to
conventional chemotherapy were randomized to paracentesis plus catumaxomab (catumaxomab) or paracentesis alone
(control) and stratified by cancer type (129 ovarian and 129 nonovarian). Catumaxomab was administered as an i.p. infusion
on Days 0, 3, 7 and 10 at doses of 10, 20, 50 and 150 lg, respectively. The primary efficacy endpoint was puncture-free
survival. Secondary efficacy parameters included time to next paracentesis, ascites signs and symptoms and overall survival (OS).
Puncture-free survival was significantly longer in the catumaxomab group (median 46 days) than the control group (median 11
days) (hazard ratio 5 0.254: p < 0.0001) as was median time to next paracentesis (77 versus 13 days; p < 0.0001). In addition,
catumaxomab patients had fewer signs and symptoms of ascites than control patients. OS showed a positive trend for the
catumaxomab group and, in a prospectively planned analysis, was significantly prolonged in patients with gastric cancer (n 5 66;
71 versus 44 days; p 5 0.0313). Although adverse events associated with catumaxomab were frequent, they were manageable,
generally reversible and mainly related to its immunologic mode of action. Catumaxomab showed a clear clinical benefit in
patients with malignant ascites secondary to epithelial cancers, especially gastric cancer, with an acceptable safety profile.
Malignant ascites results from the accumulation of ﬂuid
within the peritoneal cavity caused by the intraperitoneal
(i.p.) spread of tumor cells
1–3 and can be caused by a number
of different cancers including ovarian, gastric, endometrial,
breast, colon and pancreatic.
3 The mechanisms leading to
malignant ascites are independent of the primary tumor.
While inﬁltrating the peritoneum, tumor cells interfere with
the regulation of ﬂuid ﬂow in the peritoneal cavity. Because
of an imbalance between efﬂux and inﬂux, several liters of
ﬂuid can accumulate.
4 Ascites results in poor quality of life
because of burdensome symptoms such as abdominal swel-
ling, a permanent feeling of fullness, pain, nausea, dyspnea,
insomnia and fatigue.
1,5–7 Malignant ascites is a manifestation
of advanced disease and is associated with a poor progno-
sis.
3,8,9 Although chemotherapy is the usual ﬁrst-line treat-
ment for patients presenting with ascites,
9 there is a lack of
evidence for its efﬁcacy in patients with recurrent ascites
from randomized trials. Intraperitoneal administration of
radioisotopes or chemotherapy and peritoneovenous shunting
procedures have also been used, but the data are limited.
10,11
Paracentesis is the most common treatment for the relief of
symptoms of recurrent ascites.
10,11 However, repeated para-
centesis leads to frequent hospital admission and is associated
with several problems, including pain because of the proce-
dure, protein loss causing hypovolemia and a risk of infec-
tion, peritonitis and bowel perforation. Furthermore, because
paracentesis only provides short-term symptom relief, it has
to be repeated frequently, often once a week.
Catumaxomab is a trifunctional monoclonal antibody with
two different antigen-binding sites and a functional Fc do-
main.
12 The two speciﬁc antigen-binding sites bind to epithe-
lial tumor cells via the epithelial cell-adhesion molecule
(EpCAM) and to T-cells via CD3. Furthermore, catumaxo-
mab activates Fcc-receptor I-, IIa- and III-positive accessory
cells via its functional Fc domain.
13 The simultaneous
recruitment and activation of different immune effector cells
at the tumor site leads to improved tumor-cell elimination by
different immunologic killing mechanisms.
14 EpCAM is
expressed in the majority of epithelial cancers, making it an
attractive target for antibody therapy.
15 Tumor cells in malig-
nant effusions have been shown to express EpCAM in 70–
100% of those cases that commonly cause malignant ascites,
e.g., breast, ovarian, gastric and colorectal cancer.
16–18 EpCAM
is also expressed on cells of normal epithelial tissues.
15 How-
ever, normal EpCAM-positive tissue is assumed to be inacces-
sible to intact antibodies in vivo because of its protection by
the basal lamina.
19 In contrast, EpCAM in solid tumors is
expected to be accessible for binding with intact antibodies
after passage through the leaky tumor mosaic vessels or in
body ﬂuids such as ascites or pleural effusions. Furthermore,
the peritoneal cavity is lined by mesothelial cells that do not
express EpCAM.
20 Therefore, the i.p. administration of catu-
maxomab offers the advantage of a targeted, locoregional
immunotherapy against EpCAMþ tumor cells in the perito-
neal cavity, which are the main cause of malignant ascites.
In previous studies, catumaxomab has demonstrated efﬁ-
cacy in patients with malignant ascites with an acceptable
safety proﬁle.
21,22 This study is the ﬁrst prospective, random-
ized trial designed to compare the i.p. infusion of catumaxo-
mab plus paracentesis (C þ P) with paracentesis alone to
assess the efﬁcacy and safety of catumaxomab in the treat-
ment of malignant ascites due to epithelial cancers.
Material and Methods
Study design
This was a two-arm, randomized, open-label, phase II/III study
in patients with symptomatic malignant ascites secondary to
epithelial cancers requiring symptomatic therapeutic paracente-
sis (Fig. 1). The study (EudraCT number: 2004-000723-15;
ClinicalTrials.gov identiﬁer: NCT00836654) was approved by
an independent ethics committee at each study center, and all
patients gave written informed consent before participation.
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Int. J. Cancer: 127, 2209–2221 (2010) V C 2010 UICCThe study was conducted in compliance with Good Clinical
Practice guidelines and the Declaration of Helsinki.
Treatment
After draining the ascites ﬂuid, 500 mL of 0.9% sodium chlo-
ride solution was administered by i.p. infusion before each
catumaxomab dose to support intra-abdominal distribution
of the antibody. Based on the dose, catumaxomab was predi-
luted in an appropriate volume of 0.9% sodium chloride solu-
tion placed in a 50-mL perfusor syringe. Catumaxomab was
administered as four 6-hr constant-rate i.p. infusions at doses
of 10, 20, 50 and 150 lg on Days 0, 3, 7 and 10, respectively,
via an i.p. catheter in parallel with an infusion of 250 mL of
0.9% sodium chloride solution. All catumaxomab i.p. infu-
sions were performed in an inpatient setting. The dosing and
administration regimen was based on the results of a phase
I/II study.
22 The catheter remained in the peritoneal cavity for
all four infusions and was removed 1 day after the last infu-
sion. Before each catumaxomab infusion and 1 day after the
last infusion, the remaining ﬂuid was drained from the
Figure 1. (a) Study design. (b) CONSORT ﬂow diagram (only results for the intent-to-treat and safety populations are included in this
article). *The main cancer types in the nonovarian stratum were gastric (n ¼ 66, 51%), breast (n ¼ 13, 10%), pancreas (n ¼ 9, 7%), colon
(n ¼ 8, 6%) and endometrial (n ¼ 6, 5%).
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Int. J. Cancer: 127, 2209–2221 (2010) V C 2010 UICCperitoneal cavity via the catheter. The control group was
treated with one therapeutic paracentesis only (Day 0).
In both groups, repuncture was performed if patients
required relief of ascites symptoms. Investigators had a clear
algorithm to determine when a therapeutic paracentesis
should be performed. (i) Ascites volume >1 L based on a
computed tomography (CT) scan was estimated by the local
radiologist. This was retrospectively conﬁrmed by two inde-
pendent blinded readers and was supported by objective
measurements of collected ascites volume and changes in
body weight. The collected ascites volume was recorded and
plotted against time to determine the in vivo accumulation
rate. (ii) Symptomatic ascites based on signs (physical exami-
nation) and symptoms (ascites-speciﬁc patient questionnaire)
was assessed by the investigator.
Patients were assessed with up to ﬁve follow-up visits at 8
days and 1, 3, 5 and 7 months (end of study) after the last
infusion (catumaxomab group) or therapeutic paracentesis
(Day 0, control group). In the control group, the end of the
study was reached when the patient required the next para-
centesis or died, whichever occurred ﬁrst. For the analysis of
the primary endpoint, any patients lost to follow-up were
censored at the time of their last visit. After reaching the pri-
mary endpoint, all patients were further assessed every 2
months until death or 6 months after the last patient was
randomized, whichever was later, for the evaluation of overall
survival (OS). Patients in the control group who fulﬁlled the
eligibility criteria and had two therapeutic punctures after
Day 0 were permitted to receive catumaxomab in a subse-
quent, single-arm, crossover period (data not shown).
Endpoints
The primary efﬁcacy endpoint was puncture-free survival.
This composite endpoint was deﬁned as the time to ﬁrst
need for therapeutic puncture or death after treatment,
whichever occurred ﬁrst. Secondary efﬁcacy parameters
included time to next paracentesis, ascites signs and symp-
toms and OS. Ascites symptoms (anorexia, nausea, early sati-
ety, vomiting, abdominal pain, abdominal swelling, dyspnea,
fatigue, swollen ankles and heartburn) were assessed subjec-
tively using a patient questionnaire with a four-point Likert
scale (none, mild, moderate and severe).
23 Ascites signs
(abdominal distension dull to percussion, shifting dullness,
ﬂuid thrill and bulging ﬂanks) were assessed objectively after
abdominal examination by the investigator. The investigator
also determined whether or not the ascites was symptomatic
based on an assessment of the results of the patient question-
naire and the abdominal examination. For the ﬁnal assess-
ment of OS, the results of the poststudy period (i.e., the
period after the primary endpoint was reached) were included.
Safety was assessed by adverse event reporting throughout
the study. Adverse events were coded according to the Medi-
cal Dictionary for Regulatory Activities version 8.0. Adverse
events were graded according to the National Cancer Insti-
tute Common Toxicity Criteria (version 2.0, April 30, 1999).
Patients
Adult patients aged  18 years with histologically conﬁrmed
epithelial cancer and EpCAMþ tumor cells in the ascites
ﬂuid were eligible for inclusion in this study. Other inclusion
criteria were as follows: Karnofsky performance status  60;
life expectancy >8 weeks; estimated ascites volume >1Lb y
CT scan; at least one symptomatic paracentesis within 5 weeks
as well as an objectively veriﬁed, clinical need for a second
paracentesis and refractory or resistant to chemotherapy or
standard chemotherapy was no longer feasible. Patients were
excluded if they had: exposure to cancer chemotherapy or
radiotherapy within the previous 28 days; previous treatment
with murine monoclonal antibodies; enteral feeding at study
entry or ileus within the previous 30 days and >70% tumor
inﬁltration of the liver, or portal vein obstruction, or throm-
bosis. Patients were randomized 2:1 to paracentesis plus catu-
maxomab or paracentesis alone (control) and stratiﬁed by
cancer type (ovarian and nonovarian).
Determination of tumor-cell load
Tumor-cell load (number of EpCAMþ tumor cells/10
6 ascites
cells) in ascites ﬂuid was analyzed for both groups at screen-
ing and at puncture visit. In addition, measurements were
performed in the catumaxomab group during treatment
before the second infusion and 1 day after the last infusion.
Tumor-cell load was determined via quantiﬁcation of
EpCAMþ tumor cells in ascites ﬂuid/peritoneal lavage and
was performed using immunocytochemistry as described else-
where.
21 Brieﬂy, ascites cells were harvested by centrifugation
or ﬁcoll density centrifugation. A constant number of cells
was centrifuged on cytospin slides, and tumor cells were
labeled at screening (before therapy) with the anti-EpCAM
antibody HO-3 (the parental antibody of catumaxomab;
TRION Pharma, Munich, Germany), ensuring that the
patients’ EpCAMþ tumor cells could be recognized by catu-
maxomab. To prevent inhibition of antibody staining by catu-
maxomab residuals in ascites samples during and after ther-
apy, these samples were stained with the anti-EpCAM
antibody VU1D9 (TRION Research, Martinsried, Germany),
which recognizes a different EpCAM epitope to HO-3/catu-
maxomab. HO-3 and VU1D9 were both directly labeled with
a Texas Red ﬂuorescence dye. All cytospins were analyzed by
a computerized image analysis system (MDS
TM; Applied Imag-
ing International, Newcastle upon Tyne, UK) to count the cells
labeled with Texas Red. Leukocytes were stained with an anti-
CD45 antibody (Caltag Laboratories, Hamburg, Germany) and
its corresponding secondary antibody IgG1 Alexa Fluor 488
(Molecular Probes, Invitrogen, Karlsruhe, Germany).
Detection of antidrug antibodies
As catumaxomab is a nonhumanized mouse/rat antibody, the
development of human anti-mouse antibodies (HAMAs)
against catumaxomab was investigated. HAMAs were ana-
lyzed in serum samples at the following timepoints: at
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Int. J. Cancer: 127, 2209–2221 (2010) V C 2010 UICCscreening, before the third infusion, before the fourth infu-
sion, 8 days and 1 month after the last infusion and at punc-
ture visit. A commercially available in vitro diagnostic test,
HAMA-ELISA Medac (Medac, Hamburg, Germany), a sim-
ple and rapid one-step enzyme immunoassay for the quanti-
tative determination of HAMAs in serum, was used. The test
was performed according to the manufacturer’s instructions
and calibrated against goat anti-mouse IgG antibodies, with a
measuring range of 40–2,000 ng/mL. Brieﬂy, microtiter plates
were coated with mouse IgG and then clinical-trial samples
and peroxidase-labeled mouse IgG (conjugate) were added.
For detection of bound HAMAs, a tetramethylbenzidine sub-
strate was added. The reaction was stopped by the addition
of sulfuric acid. The absorption of the colored product was
measured photometrically at 450 nm (reference wavelength:
620–650 nm). An internal test to detect HAMAs and human
anti-rat antibodies showed a signiﬁcant correlation with the
results of the Medac test.
Statistics
The planned sample size of 216 randomized patients was
based on the following considerations: the primary efﬁcacy
variable (puncture-free survival), the duration of patient ob-
servation (7 months [30 weeks]), the median time to end of
puncture-free survival (twice the time in the catumaxomab
group than in the control group: the assumed median punc-
ture-free survival time was 5 weeks in the control group versus
10 weeks in the catumaxomab group), 10% of patients lost to
follow-up, alpha level 0.05, two-sided, no adjustment for the
two tests (ovarian and nonovarian subgroups) and a random-
ization ratio of 2:1 (catumaxomab versus control group).
All statistical tests were two-sided, and the level of signiﬁ-
cance was 5%. The evaluation of puncture-free survival in the
intent-to-treat (ITT) population (all randomized patients)
was the primary efﬁcacy analysis. The log-rank test and the
hazard ratio (HR) were used to compare puncture-free sur-
vival between the two treatment groups. The variables to
deﬁne the need for paracentesis were analyzed by chi-square
test, kappa coefﬁcients, McNemar’s test and analysis of covar-
iance (ANCOVA), as appropriate. Secondary variables were
analyzed with Kaplan-Meier estimates, log-rank test, HR, chi-
square test, Cox regression analysis, Cochran-Mantel-Haens-
zel test, ANCOVA or Wilcoxon test, as appropriate. Statisti-
cal testing for secondary variables was descriptive only. The
safety population consisted of all patients who received at
least one dose of catumaxomab or were randomized to the
control group. Data were analyzed separately for patients
with ovarian and nonovarian cancer with an additional anal-
ysis of the pooled population and a subgroup population of
the nonovarian cancer patients with gastric cancer (the larg-
est patient subgroup in the nonovarian cancer stratum).
Results
From September 2004 to August 2006, 258 patients were
randomized at 75 centers in 13 countries (ITT population):
85 to paracentesis plus catumaxomab (catumaxomab) and 44
to paracentesis alone (control) in both disease strata (129
ovarian and 129 nonovarian cancer) (Fig. 1). The main can-
cer types in the nonovarian stratum were gastric (n ¼ 66,
51%), breast (n ¼ 13, 10%), pancreas (n ¼ 9, 7%), colon
(n ¼ 8, 6%) and endometrial (n ¼ 6, 5%). Thirteen patients
in the catumaxomab group (ﬁve ovarian and eight nonovarian
cancer) were not treated and were withdrawn from the study,
but were included in the ITT population. The reasons for not
receiving catumaxomab treatment were withdrawal of con-
sent (n ¼ 5), death before treatment could be started (n ¼ 4)
and other (n ¼ 4), which included a serious adverse event,
ileus, failure to meet inclusion criteria and problems with
Table 1. Demographic and clinical characteristics at baseline (intent-to-treat population)
Characteristic
Ovarian cancer (n 5 129) Nonovarian cancer (n 5 129)
Catumaxomab plus
paracentesis (n 5 85)
Paracentesis
alone (n 5 44)
Catumaxomab plus
paracentesis (n 5 85)
Paracentesis
alone (n 5 44)
Median age, years (range) 59 (23–85) 57 (41–82) 57 (31–86) 60.5 (31–85)
Median BMI, kg/m
2 (SD) 23.9 (13.9–47.5) 24.5 (17.3–34.6) 21.6 (15–39.6) 22.1 (16.2–39.5)
Median time since diagnosis of
primary tumor, months (range)
19.0 (0–188) 23.5 (0–102) 11.0 (0–229) 11.0 (0–343)
Median time since ﬁrst diagnosis of
ascites, months (range)
7.0 (0–62) 6.5 (0–82) 2.0 (0–76) 2.0 (0–58)
Median number of ascites
drainages (range)
1 (1–10) 1 (1–9) 1 (1–9) 1 (1–10)
Median time since last therapeutic
ascites puncture, days (range)
17 (1–46) 20 (3–36) 14 (2–63) 17.5 (2–35)
Median number of previous
chemotherapies (range)
3 (0–8) 3 (1–10) 1 (0–10) 1 (0–9)
Median ascites volume at screening,
mL (range)
2,927 (80–12,683) 2,927 (98–7,000) 3,763 (130–11,473) 3,951 (355–14,000)
Karnofsky index 80–90, n (%) 45 (53) 32 (73) 47 (56) 19 (43)
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Int. J. Cancer: 127, 2209–2221 (2010) V C 2010 UICCascites drainage. All 88 patients in the control group received
a therapeutic paracentesis at Day 0. Three patients in the
control group (all nonovarian cancer) were lost to follow-up.
In total, 245 patients (157 catumaxomab and 88 control)
were included in the safety population. More than 80% of
these patients (86% [n ¼ 69] ovarian and 81% [n ¼ 62] non-
ovarian cancer) received all four planned infusions. Reasons
for patients receiving less than four infusions included
adverse events (n ¼ 20), withdrawal of patient consent (n ¼
3) and other/not known (n ¼ 3). Sixty-one percent (58%
catumaxomab; 64% control) of patients had distant metasta-
ses and 22% (21% catumaxomab; 23% control) of these
patients had liver metastases. There were no relevant differ-
ences in baseline characteristics between the treatment groups
in either strata (Table 1).
Median puncture-free survival was longer in catumaxo-
mab patients in both strata and therefore also in the pooled
analysis (46 days) compared to the control (11 days) (Fig.
2a). In the ovarian and nonovarian cancer patients, median
puncture-free survival was 52 and 37 days for paracentesis
plus catumaxomab versus 11 and 14 days for paracentesis
alone, respectively (Table 2). All differences were statistically
signiﬁcant (p < 0.0001). The HR for the pooled population
was 0.254 (95% conﬁdence interval [CI] 0.185–0.350, Table
2), corresponding to a risk reduction for puncture or death
of 75%. For the determination of puncture-free survival, 66%
of the events (133/201) were punctures and 34% (68/201)
were deaths. Puncture-free survival was also determined sepa-
rately for patients with and without distant metastases, in
particular liver metastases, and an increase was seen with
catumaxomab versus paracentesis alone: with metastases, 44
versus 13 days; without metastases, 48 versus 11 days; with
liver metastases, 27 versus 9 days and without liver metasta-
ses, 49 versus 14 days (p < 0.0001 for all comparisons).
The median time to the next therapeutic puncture was
also signiﬁcantly longer in the catumaxomab group compared
to the control: pooled population, 77 versus 13 days (HR
0.169; 95% CI 0.114–0.251) (Fig. 2b); ovarian cancer, 71
versus 11 days (HR 0.152; 95% CI 0.088–0.260) and nonovar-
ian cancer, 80 versus 15 days (HR 0.183; 95% CI 0.101–0.331;
Figure 2. Kaplan-Meier estimates of puncture-free survival, time to next paracentesis and overall survival (intent-to-treat population).
(a) Puncture-free survival in the pooled population; (b) time to next paracentesis in the pooled population; (c) overall survival in the
pooled population; (d) overall survival in patients with ovarian cancer and (e) overall survival in patients with gastric cancer.
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Int. J. Cancer: 127, 2209–2221 (2010) V C 2010 UICCp < 0.0001 for all comparisons) (Table 2). The largest differ-
ence in median time to next paracentesis was observed in
gastric cancer patients, the largest subpopulation of nonovar-
ian cancer patients: 118 versus 15 days (HR 0.143; 95% CI
0.057–0.359; p < 0.0001).
Measures implemented to objectify the timepoint of para-
centesis showed the following results. CT scans were performed
by the local radiologist for the majority of patients (catumax-
omab: 67%; control: 83%) to estimate whether the ascites vol-
ume was >1 L at the puncture visit. The concordance
between the initial CT estimation and the results of a blinded
reader was >80% in all patient groups and at all timepoints.
In >70% of patients, the ascites volume collected at the
puncture visit was >2 L. In the catumaxomab and control
groups, the median collected ascites volumes were 3,500 ver-
sus 3,251 mL, respectively, corresponding to body weight
changes of  3.0 kg for catumaxomab patients and  2.8 kg
for control patients. There was a statistically signiﬁcant dif-
ference in the median calculated daily ascites volume col-
lected in the catumaxomab versus the control group: 82 mL/
day versus 271 mL/day in the ovarian cancer stratum (p ¼
0.0006) and 55 mL/day versus 414 mL/day in the nonovarian
cancer stratum (p < 0.0001). The median percentage of
patients with reported symptomatic ascites at puncture visit
was 92% in the catumaxomab group versus 95% in the con-
trol group. In both groups, ascites signs and symptoms at
screening and puncture visit were comparable. There were
fewer ascites signs and symptoms (assessed 8 days after the last
catumaxomab infusion or after Day 0 in the control group) in
catumaxomab patients compared to the control group (Fig. 3).
In six of ten symptom categories (anorexia, nausea, early sati-
ety, abdominal pain, abdominal swelling and dyspnea) and in
all four sign categories (abdominal distension dull to percus-
sion, shifting dullness, ﬂuid thrill and bulging ﬂanks), these
differences were statistically signiﬁcant (p < 0.05).
The median OS (secondary endpoint) was 72 days for
paracentesis plus catumaxomab compared to 68 days for par-
acentesis alone (p ¼ 0.0846) in the pooled analysis (Fig. 2c,
Table 2). In the ovarian (Fig. 2d) and nonovarian cancer
strata, the median OS was 110 and 52 days for paracentesis
plus catumaxomab and 81 and 49 days for paracentesis
alone, respectively (ovarian cancer: p ¼ 0.1543; nonovarian
cancer: p ¼ 0.4226) (Table 2). The difference in OS was stat-
istically signiﬁcant in patients with gastric cancer (median 71
versus 44 days; p ¼ 0.0313) (Fig. 2e, Table 2). The HR for
the pooled population was 0.723 (95% CI 0.498–1.048), cor-
responding to a risk reduction for death of 27.7%.
EpCAMþ tumor cells in the ascites ﬂuid were signiﬁ-
cantly reduced after catumaxomab treatment to a median of
zero after the last infusion (pooled population, Fig. 4a): 95/
115 patients had a tumor-cell count of zero after the last
infusion. In contrast, the number of CD45þ leukocytes was
increased in ascites/lavage samples during and at the end of
catumaxomab treatment (Fig. 4b). The median tumor-cell
count at the repuncture visit was statistically signiﬁcantly
lower (p ¼ 0.0012) in the catumaxomab group (2,090 tumor
cells/10
6 analyzed cells; median 77 days after treatment) than
in the control group (18,929 tumor cells/10
6; median 13 days
after paracentesis). Furthermore, the median volume of asci-
tes ﬂuid produced was also reduced after catumaxomab treat-
ment. The median ascites volume drained after treatment
with catumaxomab minus the volume of the ﬁrst paracentesis
Table 2. Puncture-free survival, time to next paracentesis and overall survival
Pooled population
(n 5 258)
Ovarian cancer
(n 5 129)
Nonovarian cancer
(n 5 129)
Gastric cancer
(n 5 66)
C 1 P
(n 5 170)
P
(n 5 88)
C 1 P
(n 5 85)
P
(n 5 44)
C 1 P
(n 5 85)
P
(n 5 44)
C 1 P
(n 5 46)
P
(n 5 20)
Puncture-free survival (days)
Median (95% CI) 46 (35–53) 11 (9–16) 52 (38–62) 11 (9–20) 37 (27–49) 14 (8–17) 44 (27–69) 15 (8–21)
Factor of prolongation 4.2 4.7 2.6 2.9
p-value
1 <0.0001 <0.0001 <0.0001 <0.0001
HR, estimate (95% CI) 0.254 (0.185–0.350) 0.205 (0.129–0.327) 0.309 (0.199–0.482) 0.289 (0.151–0.554)
Time to next paracentesis (days)
Median (95% CI) 77 (62–104) 13 (9–17) 71 (52–104) 11 (9–20) 80 (64–135) 15 (8–19) 118 (64–147) 15 (8–24)
Factor of prolongation 5.9 6.4 5.3 7.9
p-value
1 <0.0001 <0.0001 <0.0001 <0.0001
HR, estimate (95% CI) 0.169 (0.114–0.251) 0.152 (0.088–0.260) 0.183 (0.101–0.331) 0.143 (0.057–0.359)
Overall survival (days)
Median (95% CI) 72 (61–98) 68 (49–81) 110 (70–164) 81 (68–134) 52 (44–74) 49 (33–68) 71 (50–98) 44 (28–68)
p-value
1 0.0846 0.1543 0.4226 0.0313
HR, estimate (95% CI) 0.723 (0.498–1.048) 0.650 (0.357–1.183) 0.825 (0.514–1.324) 0.469 (0.232–0.951)
1Log-rank test.
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Before the second and third infusions, the median drained
volume was greater than the volume infused, whereas after
the fourth infusion, the median volume drained was similar
to the volume infused (750 and 782 mL, respectively).
The safety population included 157 catumaxomab patients
and 88 control patients. As catumaxomab was effective in
prolonging puncture-free survival, the observation period for
adverse events was distinctly longer in the catumaxomab
than in the control group. Thus, comparison of adverse-event
frequencies between the treatment groups is misleading. The
pattern of adverse events in the ovarian and nonovarian can-
cer patients was similar, irrespective of the adverse events
related to the primary tumor. More than 98% of catumaxomab
patients had at least one adverse event and 85% had adverse
events considered related to study treatment (Table 3). There
was no distinctive pattern of adverse events corresponding
to speciﬁc infusions. Ninety-one patients (58%) experienced
serious adverse events, of whom 23 (15%) had serious adverse
events considered to be treatment related.
The most commonly reported catumaxomab-related
adverse events in both the ovarian and nonovarian groups
were cytokine release–related symptoms (pyrexia, nausea
and vomiting) and abdominal pain. These events were
generally mild to moderate in intensity and reversible.
There were no cases of catheter-related infections. Ten patients
experienced ileus (Grade 1: n ¼ 1; Grade 2: n ¼ 4; Grade 3: n
¼ 2 and Grade 4: n ¼ 3), and three patients experienced subi-
leus events (Grade 2: n ¼ 2 and Grade 3: n ¼ 1). Of these
patients, seven cases of ileus (Grade 2: n ¼ 2; Grade 3: n ¼ 2
and Grade 4: n ¼ 3) and two cases of subileus (both Grade 2)
were reported as serious adverse events. One patient had a Grade
3 gastric hemorrhage also reported as a serious adverse event.
There were 61 deaths (26 ovarian and 45 nonovarian can-
cer) during the study, none of which were considered related
to catumaxomab. Laboratory parameters showed similar
trends in ovarian and nonovarian cancer patients. Abnormal
liver parameters (transient increases in alanine aminotransfer-
ase, aspartate aminotransferase, alkaline phosphatase and
gamma-glutamyltransferase) and white blood cell disorders
(lymphopenia, leukocytosis and anemia) were regularly
observed. However, these laboratory abnormalities were rarely
considered clinically relevant and were generally reversible.
Before treatment with catumaxomab, plasma samples
from the vast majority (>95%) of patients were HAMA neg-
ative. Before the fourth infusion, most patients (91% [59/65]
ovarian cancer and 98% [58/59] nonovarian cancer) were still
HAMA negative. Eight days after the last catumaxomab infu-
sion, 82% (49/60) of ovarian cancer patients and 69% (36/52)
of nonovarian cancer patients were HAMA positive, whereas
1 month after the fourth infusion, 95% (36/38) of ovarian
cancer patients and 94% (30/32 ) of nonovarian cancer
patients had become HAMA positive. In patients with a posi-
tive HAMA test before the fourth infusion (n ¼ 7), there
were no obvious changes in the pattern of adverse events
reported after the last infusion.
Discussion
There is a great need for an effective treatment of malignant
ascites. Although some novel therapeutic approaches have
Figure 3. Patients without ascites signs and symptoms as assessed by interview 8 days after last infusion (catumaxomab) or 8 days after
paracentesis (control group).
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Int. J. Cancer: 127, 2209–2221 (2010) V C 2010 UICCFigure 4. (a) Tumor-cell load in the ascites ﬂuid before, during and after catumaxomab treatment. Number of EpCAMþ tumor cells per 10
6
total cells evaluated by immunocytochemistry. The median tumor-cell count at the repuncture visit was statistically signiﬁcantly lower
(p ¼ 0.0012) in the catumaxomab group. (b) Fluorescent double staining of ascites ﬂuid cells: evaluation of CD45þ leukocyte:EpCAMþ
tumor cell ratio during catumaxomab therapy. (i) Malignant ascites harvested at screening puncture (before catumaxomab treatment).
(ii) At Day 3 after 10 lg catumaxomab i.p. (iii) At Day 11 after a total of 230 lg catumaxomab i.p. Dotplot analysis: every plot resembles
a ﬂuorescence-labeled cell that was detected and counted by the computerized image analysis system.
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nant ascites, none have proved to be effective. These
approaches include the i.p. administration of interferon-a,
24,25
tumor necrosis factor (TNF)-a,
26,27 matrix metalloproteinase
inhibitors,
28 nonpathogenic infectious agents
29 and vascular
endothelial growth factor inhibitors.
30,31 However, most of the
studies were case reports, pilot studies or phase I trials. The
only randomized study, which compared i.p. TNF-a plus par-
acentesis with paracentesis alone, showed no improvement
with the addition of TNF-a.
26 To date, there have been no
randomized clinical trials demonstrating the efﬁcacy of chemo-
therapy, and there is no accepted standard treatment for
symptom relief other than repeated paracentesis. This study is
the ﬁrst prospective, randomized clinical trial in malignant as-
cites to demonstrate a beneﬁcial effect of treatment. The
results demonstrate that paracentesis plus catumaxomab had
superior efﬁcacy compared to paracentesis alone for the treat-
ment of malignant ascites in patients with epithelial cancer.
Immunotherapy with catumaxomab or bispeciﬁc antibodies
has previously been shown to be effective in preventing and/or
diminishing the accumulation of ascites and eliminating tumor
cells with an acceptable safety proﬁle in patients with
advanced ovarian cancer.
21,22,32
The primary endpoint of our study was puncture-free sur-
vival. This composite endpoint was chosen because patients
with symptomatic malignant ascites have a very short life ex-
pectancy, usually only weeks to months. The statistically sig-
niﬁcant and clinically relevant prolongation of puncture-free
survival for paracentesis plus catumaxomab compared to par-
acentesis alone in both ovarian and nonovarian cancer
patients indicates that catumaxomab treatment is beneﬁcial
for a number of different types of epithelial cancer. Although
puncture-free survival provides the most reasonable estimate
of the treatment effect in this patient population with
advanced disease, the secondary endpoint of time to next
paracentesis (a component of the primary endpoint) mainly
reﬂects the clinical relevance for the individual patient.
The time to next paracentesis was also signiﬁcantly pro-
longed for paracentesis plus catumaxomab versus paracentesis
alone in both strata. The objective measurements used to verify
the puncture timepoint, e.g., ascites volume, conﬁrmed the
need for therapeutic puncture. A comparison of the median
time to the next therapeutic puncture in the control group (13
days) with that in the catumaxomab group (77 days) indicates
that catumaxomab treatment avoided the need for approxi-
mately ﬁve punctures. This is clinically relevant, considering
the continuous protein loss and the potential risk for infection
or bowel perforation with each puncture. In addition to bene-
ﬁting from fewer punctures, patients beneﬁt from a ﬁvefold
longer time without burdensome and persistent ascites symp-
toms, such as abdominal pain, abdominal pressure, dyspnea,
nausea, vomiting and early satiety. By controlling ascites symp-
toms, catumaxomab helps to improve patients’ quality of life
and enables patients with end-stage disease to lead a more
normal daily life.
Although treatment beneﬁts with regard to OS are unlikely
in such advanced disease and the study was not powered or
designed to detect a difference in OS, the Kaplan-Meier curves
indicate that catumaxomab prolonged OS in  50% of
patients. In particular, a subgroup analysis of gastric cancer
patients, the largest subpopulation in the nonovarian stra-
tum, demonstrated a statistically signiﬁcant prolongation of
OS. One reason for this observation could be that nonovar-
ian cancer patients, including those with gastric cancer, had
fewer previous chemotherapies (median of one) compared
to ovarian cancer patients who received a median of three
previous chemotherapies. This higher degree of treatment
experience may have resulted in a less functional immune
system, with a consequent impairment of catumaxomab’s
mode of action. Catumaxomab treatment also signiﬁcantly
reduced the number of tumor cells, which are the main
cause of malignant ascites,
4 during and after treatment.
Interestingly, the number of tumor cells remained substan-
tially lower until the time of repuncture compared to the
control group, demonstrating the long-lasting immunologic
antitumor effect induced by catumaxomab. Taken together,
all the efﬁcacy parameters indicate consistent results and
show a clear clinical beneﬁt for catumaxomab in patients
Table 3. Adverse events considered related to catumaxomab
occurring in  5% of patients (N ¼ 157)
Number of patients (%)
All grades Grade  3
1
Pyrexia 95 (60.5) 9 (5.7)
Abdominal pain 67 (42.7) 15 (9.6)
Nausea 52 (33.1) 5 (3.2)
Vomiting 43 (27.4) 4 (2.5)
Lymphopenia 22 (14.0) 11 (7.0)
C-reactive protein increased 23 (14.6) 7 (4.5)
Chills 21 (13.4) 2 (1.3)
Gamma-glutamyltransferase increased 18 (11.5) 9 (5.7)
Fatigue 17 (10.8) 5 (3.2)
Diarrhea 16 (10.2) 3 (1.9)
Leukocytosis 16 (10.2) 2 (1.3)
Tachycardia 15 (9.6) 1 (0.6)
Anorexia 14 (8.9) 5 (3.2)
Blood alkaline phosphatase increased 14 (8.9) 4 (2.5)
Anemia 14 (8.9) 2 (1.3)
Hypotension 13 (8.3) 3 (1.9)
Aspartate aminotransferase increased 12 (7.6) 4 (2.5)
Alanine aminotransferase increased 10 (6.4) 3 (1.9)
Ileus 10 (6.4) 5 (3.2)
Pain 8 (5.1) 0
1Symptomatic National Cancer Institute Common Toxicity Criteria
(NCI-CTC, version 2.0, April 30, 1999) Grade 4 events were observed
as isolated cases.
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ard therapy apart from paracentesis has been established,
irrespective of the primary epithelial cancer.
Catumaxomab had acceptable tolerability without unex-
pected severe or long-lasting adverse events. More than 80%
of patients received the complete dose, which is rarely seen
with other i.p. therapies.
33 The safety results of this study
conﬁrm the speciﬁc pattern of the commonly observed catu-
maxomab adverse events that are mainly related to its immu-
nologic mode of action.
22 Symptoms (e.g., pyrexia, vomiting
and nausea) associated with the release of proinﬂammatory,
modulatory and cytotoxic cytokines were very common and
are a well-known consequence of antibody therapy in gen-
eral.
34,35 The ascending dose schedule of four infusions used
in this study was selected to improve the tolerability of catu-
maxomab, as early studies indicated that patients did not tol-
erate high starting doses because of symptoms related to
cytokine release.
22 However, cytokine-release-related symp-
toms may be positively correlated with efﬁcacy and may
serve as a predictive factor for the efﬁcacy of catumaxomab.
36
The frequent occurrence of abdominal pain with catumaxo-
mab is considered to be partly a symptom of peritoneal irri-
tation following i.p. administration.
Although the adverse events associated with catumaxomab
were frequent, they were manageable and generally reversible.
The alterations in laboratory parameters were rarely consid-
ered clinically relevant. Transiently increased liver parameters
were typically observed, which can be partially explained by
catumaxomab binding to EpCAMþ bile duct cells and the
release of cytokines.
37 The transient decrease in the periph-
eral lymphocyte count might be the result of migration of
lymphocytes into the tissue and possibly to the tumor, medi-
ated by upregulation of adhesion molecules on white blood
cells after antibody-mediated activation.
38
The development of HAMAs in response to the adminis-
tration of murine antibodies has been reported in the litera-
ture.
32,39 Therefore, as expected, most of the patients in this
study developed antibodies against the nonhumanized
mouse/rat antibody catumaxomab. Interestingly, elevated
HAMA levels after treatment of ovarian cancer patients with
the bispeciﬁc F(ab)2 OC/TR antibody were associated with
longer median survival.
40
In conclusion, treatment with four i.p. doses of C þ Pd e m -
onstrated clinically relevant beneﬁts in patients with recurrent
malignant ascites due to carcinomas of different origin. Positive
trends in OS together with its demonstrated efﬁcacy against tu-
mor cells in the peritoneal cavity support the antitumor activity
of catumaxomab and suggest that it could be even more effec-
tive if used at an earlier stage in the treatment of epithelial can-
cers. Catumaxomab showed a typical pattern of adverse events
that are mainly related to its immunologic mode of action.
However, these are both, manageable and generally reversible.
The i.p. administration of catumaxomab can be regarded as a
promising new therapy for malignant ascites.
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